Idorsia (SWX: IDIA) Reports Positive Phase 1 Data for C. difficile Vaccine, IgG Responses Surge

Idorsia Ltd (SWX: IDIA) announced on June 1, 2026, that its experimental Clostridioides difficile vaccine produced robust increases in immunoglobulin G (IgG) responses and was well tolerated in a Phase 1 study of healthy adults. The data support advancing the program into mid-to-late-stage trials. The Swiss biopharmaceutical company said the vaccine met primary safety and immunogenicity endpoints without serious adverse events. C. difficile is a leading cause of hospital-acquired diarrhea with limited prevention options, representing a significant market opportunity. Idorsia plans to begin Phase 2/3 development, though no timeline was immediately disclosed. Shares of Idorsia have declined this year amid pipeline reprioritization. Analysts consider the positive vaccine readout a potential catalyst for the infectious disease segment.